Ralph W.
- Country
- Germany
- Department
- Klinik f. Innere Medizin I Hämatologie, Onkologie u. Stammzellentransplantation
Research Overview
- Phase 1b Evaluation of Subcutaneous Daratumumab with Bispecific T Cell Redirection Antibodies in Multiple Myeloma Patients
- AZD0120 Versus Standard Regimens in Relapsed or Refractory Multiple Myeloma: A Phase III Randomised Study
- Phase 3 Randomized Study of JNJ‑79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After 1–3 Prior Lines Including Anti‑CD38 Antibody and Lenalidomide
Data & Insights
Has run more than one trial at 92 of 219 partner sites.
Specializations
Multiple Myeloma Research
This investigator specializes in treating multiple myeloma, with particular emphasis on both newly diagnosed and relapsed/refractory cases. Their research encompasses innovative therapeutic combinations including novel agents and standard treatments.
- Newly Diagnosed Multiple Myeloma (NDMM)
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Stem Cell Transplantation Approaches
The investigator explores combination therapies involving proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
Advanced Therapeutics
Their work involves evaluating novel therapeutic approaches including bispecific antibodies and cellular therapies. The research focuses on optimizing drug delivery methods and improving treatment outcomes.
- Subcutaneous Drug Administration
- Targeted Therapies
- Immunotherapy Approaches
Special attention is given to developing personalized treatment strategies for different patient populations.
Acute Lymphoblastic Leukemia
The investigator conducts research in acute lymphoblastic leukemia (ALL), with specific focus on Philadelphia-chromosome positive and B-cell variants.
- Ph+ ALL Treatment Strategies
- B-cell ALL Therapeutics
- Novel Agent Development
Research includes evaluation of tyrosine kinase inhibitors and innovative therapeutic combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.